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ABSTRACT 
Background 
To report our experience utilizing a multidisciplinary clinic (MDC) at Indiana University 
(IU) since the publication of the International Germ Cell Cancer Collaborative Group 
(IGCCCG), and to compare our overall survival to that of the National Cancer Institute 
(NCI) Surveillance, Epidemiology, and End Results (SEER) Program.  
Patients and Methods  
We conducted a retrospective analysis of all patients with metastatic germ cell tumor 
(GCT) seen at IU from 1998-2014. 1,611 consecutive patients were identified, of whom 
704 patients received an initial evaluation by our MDC (including medical oncology, 
pathology, urology and thoracic surgery) and started first-line chemotherapy at IU.  
These 704 patients were eligible for analysis. All patients in this cohort were treated with 
cisplatin-etoposide based combination chemotherapy. We compared the progression-
free survival (PFS) and overall survival (OS) of patients treated at IU with that of the 
published IGCCCG cohort. OS of the IU testis cancer primary cohort (n=622) was 
further compared to the SEER data of 1283 patients labeled with “distant” disease. The 
Kaplan-Meier method was used to estimate progression-free survival and overall 
survival.  
Results 
With a median follow-up of 4.4 years, patients with good, intermediate, and poor risk 
disease by IGCCCG criteria treated at IU had 5-year PFS of 90%, 84%, and 54% and 5-
year OS of 97%, 92%, and 73% respectively. The 5-year PFS for all patients in the IU 
Page 3 of 35 Annals of Oncology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
3 
cohort was 79% (95%CI, 76% to 82%). The 5-year OS for the IU cohort was 90% (95% 
CI, 87% to 92%). IU testis cohort had 5-year OS 94% (95% CI, 91% to 96%)  vs. 75% 
(95% CI, 73% to 78%) for the SEER “distant” cohort between 2000-2014, P-value 
<0.0001. 
Conclusion 
The MDC approach to GCT at high-volume cancer center associated with improved 
overall survival outcomes in this contemporary dataset. OS is significantly higher in the 
IU cohort compared to the IGCCCG and SEER “distant” cohort. 
Keywords: Testicular cancer; Germ cell tumor; IGCCCG; Multidisciplinary, SEER 
Key message 
Herein, we investigated the role of multidisciplinary clinic approach in improving the 
outcomes of patients with metastatic germ cell tumors at our high volume cancer center 
at Indiana University (IU) and observed a better survival compared to the historical 
IGCCCG and the SEER distant cohort. 
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INTRODUCTION 
Germ-cell tumors (GCT) are the most common cancer in men between 15 and 35 years 
of age, with an estimated 8,720 cases diagnosed annually in the United States and 410 
deaths [1]. First-line chemotherapy with bleomycin-etoposide-cisplatin (BEP) became 
the standard of care for patients with advanced GCT [2-5]. The International Germ-Cell 
Cancer Collaborative Group (IGCCCG) in 1997 published a consensus statement 
classifying patients with metastatic GCT into good, intermediate, and poor risk disease 
[6]. Good risk GCT had a 5-year progression-free survival (PFS) of 88% and a 5-year 
overall survival (OS) of 91%. Intermediate risk GCT had a 5-year PFS of 75% and a 5-
year OS of 79%. The poor risk category had a 5-year PFS of 41% and a 5-year OS of 
48%. 
The optimal management of germ cell tumors is complex, with options including 
chemotherapy and surgery. At Indiana University Cancer Center (IU), we have 
established a multidisciplinary clinic (MDC) to evaluate newly diagnosed GCT patients 
and those needing additional consultation. The goals of this MDC are to provide state-
of-the-art oncology care and to educate patients, their families, medical students, 
residents, and fellows in training. Our MDC integrate dedicated team including medical 
oncologists, pathologists, urologic and thoracic surgical oncologists, full-time 
coordinator (responsible for data acquisition, scheduling, and following up with patients 
and referring physicians) and oncology nurses. The team meets on a weekly basis in a 
multidisciplinary tumor board. Through this clinic, we can establish the accurate 
pathological diagnosis, offer combination chemotherapy, surgical resection of residual 
tumor and enroll patients on clinical trials all in one visit (Figure S2). 
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Institutional experience, hospital and physician volume have been associated with 
improved outcomes of testicular cancer [7-10]. Recent outcome data from large 
datasets are missing, and the difference in results of patients treated in large volume 
centers and community centers is unknown. We, therefore, report survival outcomes in 
704 consecutive patients with metastatic GCT treated at our MDC at IU since the 
publication of IGCCCG and compare the outcome to those of National Cancer Institute 
(NCI) Surveillance, Epidemiology, and End Results (SEER) Program. 
PATIENTS AND METHODS 
Patients 
The IU Cancer Registry database was queried, and a retrospective review was 
performed to compare the PFS and OS of patients treated at IU with that of IGCCCG 
[6]. This study used the secure Web-based, Title 21 Code of Federal Regulations Part 
11–compliant Research Electronic Data Capture (REDCap) system for data input. 
Eligible patients who had metastatic GCT treated at IU after the establishment of 
IGCCCG between January 1998 and December 2014 were included. All patients were 
treated with standard cisplatin-etoposide based combination chemotherapy consisting 
of at least 3-4 cycles of cisplatin and etoposide with or without bleomycin or ifosfamide 
[11, 12]. SEER Research Data (1973-2014) was also obtained to compare OS of the IU 
cohort the SEER distant cohort. The SEER distant cohort consisted of patients in the 
SEER database with testis cancer diagnosed between 2000-2014, who had a SEER 
historical stage of distant, and who had available survival data [13]. 
Statistical Analysis 
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The endpoints of the study were the PFS and OS probabilities at 5 years. For the IU 
cohort, PFS started with the initiation of chemotherapy and ended with progression or 
death, whichever occurred first. OS started with the initiation of chemotherapy and 
ended with the death of a patient. Survival status was identified from medical charts or 
death certificates. Patients without an event were censored at the date of last follow-up. 
For the SEER distant cohort, OS started with the date of diagnosis and ended with the 
death of a patient. Patients alive at the date of last contact were censored. PFS and OS 
were calculated according to the Kaplan-Meier method and using the log-rank test. 
Analyses were completed compared using SAS software, version 9.4 and figures were 
created in R, version 3.3.2. Five-year PFS and OS were reported along with 95% 
confidence intervals calculated using the log-log method. 
RESULTS 
Patient and Disease Characteristics 
For the IU cohort, 1611 consecutive patients with metastatic GCT were evaluated in the 
MDC at IU between 1998 and 2014. Of these, 704 patients started the initial 
chemotherapy at IU and were included in the primary outcome analysis (Figure S1). 
Median age at diagnosis was 29 (range 13-62). Median follow-up time was 4.4 years. 
The primary tumor site was testis in 622 (88.4%), retroperitoneum in 26 (3.7%), and 
mediastinum in 54 (7.7%). 85% had non-seminomatous GCT (NSGCT). 97% of patients 
were white, 1% were black, and the remaining 2% were a variety of races/ethnicities. Of 
note, we did not include LDH in our database. Elevations in LDH are highly nonspecific 
and may be found in a vast number of benign and malignant conditions [14]. Table 1 
lists patients and disease characteristics at the time of initiation of first-line 
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chemotherapy. Figure S3 presents a map of the United States showing the zip codes of 
patients seen at our center. 
For the SEER distant cohort, 1283 patients were identified from the SEER database 
with testis cancer diagnosed between 2000-2014. To be included in the cohort, patients 
must have had a SEER historical stage of distant and available survival data. Patients 
with a survival time of 0 (i.e., date of diagnosis and date of last contact are the same) 
were excluded. Median age at diagnosis was 32 (range 0-87). 87% of patients were 
white, 5% were black, and the remaining 8% were a variety of races/ethnicities. 73.5% 
had NSGCT. 
Treatment Administration 
All 704 evaluable patients in the IU cohort were treated with cisplatin-etoposide 
combination chemotherapy. Details regarding first-line treatment regimen stratified per 
IGCCCG risk classification are listed in Table 1. Overall, 82% of patients achieved a 
complete response (CR) and remained disease-free after first-line chemotherapy. A 
total of 250 patients (36%) underwent post-chemotherapy retroperitoneal lymph node 
dissection (PCRPLND), 129 (18%) thoracic surgery, 21 cervical lymph node dissection 
and nine patients had a resection of brain metastasis. 153 patients failed first-line 
chemotherapy, 118 received salvage chemotherapy including high dose chemotherapy 
(HDCT) (n=76), and 51 had salvage surgery. At last follow-up, 635 patients (90%) had 
no evidence of disease (NED), 65 patients (9%) had died, and four patients (1%) were 
alive with relapsed disease. Among patients who died, 52 patients were dead of disease 
progression, and 13 patients died of other causes including treatment-related toxicity, 
secondary malignancy or surgical complications. 
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We also reviewed the GCT patients who came to IU for a second opinion. 907 patients 
sought a second opinion or were evaluated after receiving first-line therapy at an 
outside institution and were not included in the primary analysis. 492 (56%) underwent 
PCRPLND, 432 (51%) underwent salvage chemotherapy, and 172 (21%) underwent 
thoracic surgery as a result of the multidisciplinary evaluation. 
Survival Outcomes 
With a median follow-up of 4.4 years, the estimated 5-year PFS was 79% (95%CI, 76% 
to 82%) and the 5-year OS was 90% (95% CI, 87% to 92%) for the IU cohort (Table 2). 
The 5-year PFS for good, Intermediate and poor risk were 90%, 84%, and 54% 
respectively (Figure 1A) and the estimated 5-year OS was 97%, 92%, and 73% (Figure 
1B), respectively. In sub-segment of patients with testis as the primary site at 
presentation (IU testis cohort n=622), the 5-year OS was 94% (95% CI, 91% to 96%). 
Patients with primary mediastinal non-seminomatous GCT (PMNSGCT) had an 
estimated 5-year PFS of 50% (95% CI, 35% to 63%) and 5-year OS of 59% (43% to 
72%). Patients with brain metastasis at diagnosis had an estimated 5-year PFS of 15% 
(5% to 28%) and 5-year OS of 46% (28% to 63%). 
To demonstrate the impact of our MDC approach, we compared OS of patients in the IU 
testicular primary cohort with the SEER distant cohort. The 5-Year OS for the SEER 
distant cohort was 75% (95% CI, 73% to 78%) compared to 94% (95% CI, 91% to 96%) 
for IU testis cohort (P-value <0.0001; Figure 2). The SEER database does not allow 
stratification according to IGCCCG risk category; therefore comparisons of survival 
between groups are not possible. 
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DISCUSSION 
To our knowledge, this is the largest single-institution study evaluating survival 
outcomes of patients with metastatic GCT. Survival results of patients treated at IU 
appear superior to the results of the IGCCCG (Table 2) and the NCI SEER distant 
cohort (Figure 2). This observation is supported by a large multi-institutional initiative 
that provided outcome results from high-volume centers that were superior to the 
original IGCCCG [15].  These data were, however, not directly compared to community 
outcomes. Several factors may account for excellent survival outcomes seen at our 
center compared to the IGCCCG and SEER database. This could be attributed to the 
uniform utilization of cisplatin-etoposide based combination chemotherapy, 
improvement in supportive care avoiding delays between cycles, expertise in post-
chemotherapy surgical resection of residual disease and the experience resulting from a 
large volume of patients. Our dedicated multidisciplinary team of medical, urologic and 
thoracic oncologists and pathologists have specific academic interest in GCT supported 
by strong research and clinical trials designed to refine treatment, improve supportive 
care, and patient education.  
Surgical treatment is crucial for the management of metastatic GCT to improve survival 
and reduce complications [16, 17]. Appropriate patient selection and timing of surgery 
have lowered morbidity while improving oncologic outcomes at high volume centers [18, 
19]. The marked improvement in OS in all-risk categories maybe driven by the 
development of successful salvage therapy options including salvage surgery, and the 
long-term experience in HDCT followed by autologous peripheral blood stem cell 
transplant (PBSCT) [20-25].  
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This analysis has limitations. This is a retrospective single institution study, and 
potential bias exists in our patient population. We didn’t have access to matched 
patient’s characteristics between the contemporary IU cohort and the historical IGCCCG 
cohort, and the community patients reported in SEER. Referral bias might have affected 
the results of this study. However, this study has a large sample size of consecutive 
patients with metastatic GCT treated at a tertiary care center with long follow-up. A large 
portion of patients enrolled in the study had poor risk disease 25.7% compared to 14% 
of patients from the IGCCCG [6]; hence survival outcomes for patients treated at other 
institutions or in the community might vary. Besides, a limitation of this study is that NCI 
SEER uses a staging system including local, regional and distant metastases which are 
not typically used in germ cell tumor. The IGCCCG classification of good, intermediate 
and poor risk is not included in the SEER database which makes further analysis not 
possible. That is why we compared all patients with metastatic disease as one group. 
Despite substantial improvement in outcomes of patients with metastatic GCT treated in 
the modern era, many challenges remain. There is a clear disparity in health care 
outcomes among patients with testis cancer [26-28]. This could be related to patient’s 
factors such as under insurance, poor socioeconomic status, ethnicity, and a language 
barrier that delays diagnosis. Also, it could be attributed to the rare nature of this cancer 
and lack of experience in the community to establish an accurate diagnosis and deliver 
a treatment plan. 
In conclusion, in this modern cohort of newly diagnosed metastatic GCT, there was an 
improvement in PFS and OS for good, intermediate, and poor-risk disease compared to 
IGCCCG. Furthermore, we demonstrated that a multidisciplinary team care approach 
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are associated with improved survival outcomes compared to SEER distant cohort. 
Taken together, these data support reconstructing health delivery models to enhance 
value and improve clinical outcomes [9, 19]. 
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FIGURE LEGENDS 
- Figure. 1: Kaplan-Meier estimates of progression-free survival (A) and overall survival
(B) according to IGCCCG risk stratification
- Figure. 2: Kaplan-Meier estimates of overall survival of patients with newly diagnosed
metastatic testicular GCT at the IU (1998-2014) and patients in NCI SEER (2000-2014). 
Online Only 
- Figure. S1: Study flow chart of 704 patients with metastatic germ-cell tumor treated at
Indiana University between 1998 and 2014 
- Figure S2: Diagram of the patients flow through the multidisciplinary GCT clinic.
- Figure S3: Map of the United States based on the zip codes of patients seen at our
MDC. 
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ABSTRACT 
Background 
To report our experience utilizing a multidisciplinary clinic (MDC) at Indiana University 
(IU) since the publication of the International Germ Cell Cancer Collaborative Group 
(IGCCCG), and to compare our overall survival to that of the National Cancer Institute 
(NCI) Surveillance, Epidemiology, and End Results (SEER) Program. 
Patients and Methods 
We conducted a retrospective analysis of all patients with metastatic germ cell tumor 
(GCT) seen at IU from 1998-2014. 1,611 consecutive patients were identified, of whom 
704 patients received an initial evaluation by our MDC (including medical oncology, 
pathology, urology and thoracic surgery) and started first-line chemotherapy at IU. 
These 704 patients were eligible for analysis. All patients in this cohort were treated with 
cisplatin-etoposide based combination chemotherapy. We compared the progression-
free survival (PFS) and overall survival (OS) of patients treated at IU with that of the 
published IGCCCG cohort. OS of the IU testis cancer primary cohort (n=622) was 
further compared to the SEER data of 1283 patients labeled with “distant” disease. The 
Kaplan-Meier method was used to estimate progression-free survival and overall 
survival. 
Results 
With a median follow-up of 4.4 years, patients with good, intermediate, and poor risk 
disease by IGCCCG criteria treated at IU had 5-year PFS of 90%, 84%, and 54% and 5-
year OS of 97%, 92%, and 73% respectively. The 5-year PFS for all patients in the IU 
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cohort was 79% (95%CI, 76% to 82%). The 5-year OS for the IU cohort was 90% (95% 
CI, 87% to 92%). IU testis cohort had 5-year OS 94% (95% CI, 91% to 96%) vs. 75% 
(95% CI, 73% to 78%) for the SEER “distant” cohort between 2000-2014, P-value 
<0.0001. 
Conclusion 
The MDC approach to GCT at high-volume cancer center associated with improved 
overall survival outcomes in this contemporary dataset. OS is significantly higher in the 
IU cohort compared to the IGCCCG and SEER “distant” cohort. 
Keywords: Testicular cancer; Germ cell tumor; IGCCCG; Multidisciplinary, SEER 
Key message 
Herein, we investigated the role of multidisciplinary clinic approach in improving the 
outcomes of patients with metastatic germ cell tumors at our high volume cancer center 
at Indiana University (IU) and observed a better survival compared to the historical 
IGCCCG and the SEER distant cohort. 
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INTRODUCTION 
Germ-cell tumors (GCT) are the most common cancer in men between 15 and 35 years 
of age, with an estimated 8,720 cases diagnosed annually in the United States and 410 
deaths [1]. First-line chemotherapy with bleomycin-etoposide-cisplatin (BEP) became 
the standard of care for patients with advanced GCT [2-5]. The International Germ-Cell 
Cancer Collaborative Group (IGCCCG) in 1997 published a consensus statement 
classifying patients with metastatic GCT into good, intermediate, and poor risk disease 
[6]. Good risk GCT had a 5-year progression-free survival (PFS) of 88% and a 5-year 
overall survival (OS) of 91%. Intermediate risk GCT had a 5-year PFS of 75% and a 5-
year OS of 79%. The poor risk category had a 5-year PFS of 41% and a 5-year OS of 
48%. 
The optimal management of germ cell tumors is complex, with options including 
chemotherapy and surgery. At Indiana University Cancer Center (IU), we have 
established a multidisciplinary clinic (MDC) to evaluate newly diagnosed GCT patients 
and those needing additional consultation. The goals of this MDC are to provide state-
of-the-art oncology care and to educate patients, their families, medical students, 
residents, and fellows in training. Our MDC integrate dedicated team including medical 
oncologists, pathologists, urologic and thoracic surgical oncologists, full-time 
coordinator (responsible for data acquisition, scheduling, and following up with patients 
and referring physicians) and oncology nurses. The team meets on a weekly basis in a 
multidisciplinary tumor board. Through this clinic, we can establish the accurate 
pathological diagnosis, offer combination chemotherapy, surgical resection of residual 
tumor and enroll patients on clinical trials all in one visit (Figure S2). 
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Institutional experience, hospital and physician volume have been associated with 
improved outcomes of testicular cancer [7-10]. Recent outcome data from large 
datasets are missing, and the difference in results of patients treated in large volume 
centers and community centers is unknown. We, therefore, report survival outcomes in 
704 consecutive patients with metastatic GCT treated at our MDC at IU since the 
publication of IGCCCG and compare the outcome to those of National Cancer Institute 
(NCI) Surveillance, Epidemiology, and End Results (SEER) Program. 
PATIENTS AND METHODS 
Patients 
The IU Cancer Registry database was queried, and a retrospective review was 
performed to compare the PFS and OS of patients treated at IU with that of IGCCCG 
[6]. This study used the secure Web-based, Title 21 Code of Federal Regulations Part 
11–compliant Research Electronic Data Capture (REDCap) system for data input. 
Eligible patients who had metastatic GCT treated at IU after the establishment of 
IGCCCG between January 1998 and December 2014 were included. All patients were 
treated with standard cisplatin-etoposide based combination chemotherapy consisting 
of at least 3-4 cycles of cisplatin and etoposide with or without bleomycin or ifosfamide 
[11, 12]. SEER Research Data (1973-2014) was also obtained to compare OS of the IU 
cohort the SEER distant cohort. The SEER distant cohort consisted of patients in the 
SEER database with testis cancer diagnosed between 2000-2014, who had a SEER 
historical stage of distant, and who had available survival data [13]. 
Statistical Analysis 
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The endpoints of the study were the PFS and OS probabilities at 5 years. For the IU 
cohort, PFS started with the initiation of chemotherapy and ended with progression or 
death, whichever occurred first. OS started with the initiation of chemotherapy and 
ended with the death of a patient. Survival status was identified from medical charts or 
death certificates. Patients without an event were censored at the date of last follow-up. 
For the SEER distant cohort, OS started with the date of diagnosis and ended with the 
death of a patient. Patients alive at the date of last contact were censored. PFS and OS 
were calculated according to the Kaplan-Meier method and using the log-rank test. 
Analyses were completed compared using SAS software, version 9.4 and figures were 
created in R, version 3.3.2. Five-year PFS and OS were reported along with 95% 
confidence intervals calculated using the log-log method. 
RESULTS 
Patient and Disease Characteristics 
For the IU cohort, 1611 consecutive patients with metastatic GCT were evaluated in the 
MDC at IU between 1998 and 2014. Of these, 704 patients started the initial 
chemotherapy at IU and were included in the primary outcome analysis (Figure S1). 
Median age at diagnosis was 29 (range 13-62). Median follow-up time was 4.4 years. 
The primary tumor site was testis in 622 (88.4%), retroperitoneum in 26 (3.7%), and 
mediastinum in 54 (7.7%). 85% had non-seminomatous GCT (NSGCT). 97% of patients 
were white, 1% were black, and the remaining 2% were a variety of races/ethnicities. Of 
note, we did not include LDH in our database. Elevations in LDH are highly nonspecific 
and may be found in a vast number of benign and malignant conditions [14]. Table 1 
lists patients and disease characteristics at the time of initiation of first-line 
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chemotherapy. Figure S3 presents a map of the United States showing the zip codes of 
patients seen at our center. 
For the SEER distant cohort, 1283 patients were identified from the SEER database 
with testis cancer diagnosed between 2000-2014. To be included in the cohort, patients 
must have had a SEER historical stage of distant and available survival data. Patients 
with a survival time of 0 (i.e., date of diagnosis and date of last contact are the same) 
were excluded. Median age at diagnosis was 32 (range 0-87). 87% of patients were 
white, 5% were black, and the remaining 8% were a variety of races/ethnicities. 73.5% 
had NSGCT. 
Treatment Administration 
All 704 evaluable patients in the IU cohort were treated with cisplatin-etoposide 
combination chemotherapy. Details regarding first-line treatment regimen stratified per 
IGCCCG risk classification are listed in Table 1. Overall, 82% of patients achieved a 
complete response (CR) and remained disease-free after first-line chemotherapy. A 
total of 250 patients (36%) underwent post-chemotherapy retroperitoneal lymph node 
dissection (PCRPLND), 129 (18%) thoracic surgery, 21 cervical lymph node dissection 
and nine patients had a resection of brain metastasis. 153 patients failed first-line 
chemotherapy, 118 received salvage chemotherapy including high dose chemotherapy 
(HDCT) (n=76), and 51 had salvage surgery. At last follow-up, 635 patients (90%) had 
no evidence of disease (NED), 65 patients (9%) had died, and four patients (1%) were 
alive with relapsed disease. Among patients who died, 52 patients were dead of disease 
progression, and 13 patients died of other causes including treatment-related toxicity, 
secondary malignancy or surgical complications. 
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We also reviewed the GCT patients who came to IU for a second opinion. 907 patients 
sought a second opinion or were evaluated after receiving first-line therapy at an 
outside institution and were not included in the primary analysis. 492 (56%) underwent 
PCRPLND, 432 (51%) underwent salvage chemotherapy, and 172 (21%) underwent 
thoracic surgery as a result of the multidisciplinary evaluation. 
Survival Outcomes 
With a median follow-up of 4.4 years, the estimated 5-year PFS was 79% (95%CI, 76% 
to 82%) and the 5-year OS was 90% (95% CI, 87% to 92%) for the IU cohort (Table 2). 
The 5-year PFS for good, Intermediate and poor risk were 90%, 84%, and 54% 
respectively (Figure 1A) and the estimated 5-year OS was 97%, 92%, and 73% (Figure 
1B), respectively. In sub-segment of patients with testis as the primary site at 
presentation (IU testis cohort n=622), the 5-year OS was 94% (95% CI, 91% to 96%). 
Patients with primary mediastinal non-seminomatous GCT (PMNSGCT) had an 
estimated 5-year PFS of 50% (95% CI, 35% to 63%) and 5-year OS of 59% (43% to 
72%). Patients with brain metastasis at diagnosis had an estimated 5-year PFS of 15% 
(5% to 28%) and 5-year OS of 46% (28% to 63%). 
To demonstrate the impact of our MDC approach, we compared OS of patients in the IU 
testicular primary cohort with the SEER distant cohort. The 5-Year OS for the SEER 
distant cohort was 75% (95% CI, 73% to 78%) compared to 94% (95% CI, 91% to 96%) 
for IU testis cohort (P-value <0.0001; Figure 2). The SEER database does not allow 
stratification according to IGCCCG risk category; therefore comparisons of survival 
between groups are not possible. 
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DISCUSSION 
To our knowledge, this is the largest single-institution study evaluating survival 
outcomes of patients with metastatic GCT. Survival results of patients treated at IU 
appear superior to the results of the IGCCCG (Table 2) and the NCI SEER distant 
cohort (Figure 2). This observation is supported by a large multi-institutional initiative 
that provided outcome results from high-volume centers that were superior to the 
original IGCCCG [15].  These data were, however, not directly compared to community 
outcomes. Several factors may account for excellent survival outcomes seen at our 
center compared to the IGCCCG and SEER database. This could be attributed to the 
uniform utilization of cisplatin-etoposide based combination chemotherapy, 
improvement in supportive care avoiding delays between cycles, expertise in post-
chemotherapy surgical resection of residual disease and the experience resulting from a 
large volume of patients. Our dedicated multidisciplinary team of medical, urologic and 
thoracic oncologists and pathologists have specific academic interest in GCT supported 
by strong research and clinical trials designed to refine treatment, improve supportive 
care, and patient education. 
Surgical treatment is crucial for the management of metastatic GCT to improve survival 
and reduce complications [16, 17]. Appropriate patient selection and timing of surgery 
have lowered morbidity while improving oncologic outcomes at high volume centers [18, 
19]. The marked improvement in OS in all-risk categories maybe driven by the 
development of successful salvage therapy options including salvage surgery, and the 
long-term experience in HDCT followed by autologous peripheral blood stem cell 
transplant (PBSCT) [20-25]. 
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This analysis has limitations. This is a retrospective single institution study, and 
potential bias exists in our patient population. We didn’t have access to matched 
patient’s characteristics between the contemporary IU cohort and the historical IGCCCG 
cohort, and the community patients reported in SEER. Referral bias might have affected 
the results of this study. However, this study has a large sample size of consecutive 
patients with metastatic GCT treated at a tertiary care center with long follow-up. A large 
portion of patients enrolled in the study had poor risk disease 25.7% compared to 14% 
of patients from the IGCCCG [6]; hence survival outcomes for patients treated at other 
institutions or in the community might vary. Besides, a limitation of this study is that NCI 
SEER uses a staging system including local, regional and distant metastases which are 
not typically used in germ cell tumor. The IGCCCG classification of good, intermediate 
and poor risk is not included in the SEER database which makes further analysis not 
possible. That is why we compared all patients with metastatic disease as one group. 
Despite substantial improvement in outcomes of patients with metastatic GCT treated in 
the modern era, many challenges remain. There is a clear disparity in health care 
outcomes among patients with testis cancer [26-28]. This could be related to patient’s 
factors such as under insurance, poor socioeconomic status, ethnicity, and a language 
barrier that delays diagnosis. Also, it could be attributed to the rare nature of this cancer 
and lack of experience in the community to establish an accurate diagnosis and deliver 
a treatment plan. 
In conclusion, in this modern cohort of newly diagnosed metastatic GCT, there was an 
improvement in PFS and OS for good, intermediate, and poor-risk disease compared to 
IGCCCG. Furthermore, we demonstrated that a multidisciplinary team care approach 
Page 24 of 35Annals of Oncology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
11 
are associated with improved survival outcomes compared to SEER distant cohort. 
Taken together, these data support reconstructing health delivery models to enhance 
value and improve clinical outcomes [9, 19]. 
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FIGURE LEGENDS 
- Figure. 1: Kaplan-Meier estimates of progression-free survival (A) and overall survival
(B) according to IGCCCG risk stratification
- Figure. 2: Kaplan-Meier estimates of overall survival of patients with newly diagnosed
metastatic testicular GCT at the IU (1998-2014) and patients in NCI SEER (2000-2014). 
Online Only 
- Figure. S1: Study flow chart of 704 patients with metastatic germ-cell tumor treated at
Indiana University between 1998 and 2014 
- Figure S2: Diagram of the patients flow through the multidisciplinary GCT clinic.
- Figure S3: Map of the United States based on the zip codes of patients seen at our
MDC. 
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Figure. 1 (A) 
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Figure. 1 (B) 
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Figure 2 
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Table 1. Patient and disease characteristics at the beginning of first-line chemotherapy 
CHARACTERISTIC OVERALL 
(N=704) 
GOOD+ 
(N=449; 
63.8%) 
INTERMEDIATE+
(N=74; 
10.5%) 
POOR+ 
(N=181; 
25.7%) 
MEDIAN AGE (RANGE) 29.3 
(13.1-61.5) 
30.54 
(14.9-
61.5) 
26.8 
(16.0-49.6) 
26.9 
(13.1-55.7) 
LOCATION OF PRIMARY 
TUMOR 
• TESTIS
• RETROPERITONEUM
• MEDIASTINUM
• UNKNOWN
622 (88.4%) 
26 (3.7%) 
54 (7.7%) 
2 (0.2%) 
433 
(96.4%) 
9 (2.0%) 
5 (1.1%) 
2 (0.5%) 
70 (94.6%) 
3 (4.0%) 
1 (1.4%) 
0 
119 
(65.8%) 
14 (7.7%) 
48 (26.5%) 
0 
TUMOR HISTOLOGY 
• SEMINOMA
• NSGCT
106 (15.1%) 
598 (84.9%) 
99 
(22.1%) 
350 
(77.9%) 
7 (9.5%) 
67 (90.5%) 
0 
181 (100%) 
PREDOMINANT HISTOLOGY 
• EMBRYONAL
• CHORIOCARCINOMA
• YOLK SAC TUMOR
• TERATOMA
• MIXED
• SEMINOMA
• PURE SEMINOMA
• NECROSIS
• IGCN (CIS)
257 (36.5%) 
48 (6.8%) 
69 (9.8%) 
65 (9.2%) 
104 (14.8%) 
63 (9.0%) 
79 (11.2%) 
11 (1.6%) 
8 (1.1%) 
205 
(45.7%) 
1 (0.2%) 
16 (3.6%) 
29 (6.5%) 
53 
(11.8%) 
59 
(13.1%) 
74 
(16.5%) 
5 (1.1%) 
7 (1.6%) 
22 (29.7%) 
5 (6.8%) 
9 (12.2%) 
7 (9.5%) 
21 (28.4%) 
3 (4.0%) 
5 (6.8%) 
2 (2.7%) 
0 
30 (16.6%) 
42 (23.2%) 
44 (24.3%) 
29 (16.0%) 
30 (16.6%) 
1 (0.6%) 
0 
4 (2.2%) 
1 (0.6%) 
MEDIAN SERUM AFP NG/ML 
(RANGE) 
10.8 
(0.2-280000) 
5.9 
(0.2-999) 
1323.6 
(0.6-9653) 
270.3 
(0.9-
280000) 
SERUM AFP 
• < 1,000
• 1,000-10,000
• ≥ 10,000
578 (82.8%) 
79 (11.3%) 
41 (5.9%) 
444 
(100%) 
0 
0 
29 (39.2%) 
45 (60.8%) 
0 
105 
(58.3%) 
34 (18.9%) 
41 (22.8%) 
MEDIAN SERUM HCG MIU/ML 
(RANGE) 
21.7 
(0-1700000) 
6.2 
(0-4981.9) 
1334.5 
(0-41000) 
10838.0 
(0.5-
1700000) 
SERUM HCG 
• < 5,000
• 5,000-50,000
• ≥ 50,000
571 (81.8%) 
51 (7.3%) 
76 (10.9%) 
444 
(100%) 
0 
0 
44 (59.5%) 
30 (40.5%) 
0 
83 (46.1%) 
21 (11.7%) 
76 (42.2%) 
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METASTATIC SITE(S) 
• RETROPERITONEUM
• PULMONARY
• NPVM
-LIVER
-BRAIN *
-BONE *
-OTHER
555 (78.8%) 
270 (38.4%) 
93 (13.2%) 
60 (8.5%) 
34 (4.8%) 
16 (2.3%) 
12 (1.7%) 
362 
(80.6%) 
96 
(21.4%) 
0 
0 
0 
0 
0 
68 (91.9%) 
41 (55.4%) 
5 (6.8%) 
1 (1.4%) 
3 (4.1%) 
2 (2.7%) 
1 (1.4%) 
125 
(69.1%) 
133 
(73.5%) 
88 (48.6%) 
59 (32.6%) 
31 (17.1%) 
14 (7.7%) 
11 (6.1%) 
FIRST-LINE CHEMOTHERAPY 
• BEPX3
• BEPX4
• BEPX3+EPX1
• EPX4
• VIPX4
• OTHER
384 (54.6%) 
123 (17.5%) 
69 (9.8%) 
42 (6.0%) 
50 (7.1%) 
36 (5.1%) 
371 
(82.6%) 
6 (1.3%) 
15 (3.3%) 
41 (9.1%) 
0 
16 (3.6%) 
7 (9.5%) 
26 (35.1%) 
33 (44.6%) 
1 (1.3%) 
2 (2.7%) 
5 (6.8%) 
6 (3.3%) 
91 (50.3%) 
21 (11.6%) 
0 
48 (26.5%) 
15 (8.3%) 
ABBREVIATIONS: NPVM, NON-PULMONARY VISCERAL METASTASIS; IGCCCG, INTERNATIONAL 
GERM CELL CANCER COLLABORATIVE GROUP; AFP, ALPHA FETOPROTEIN; HCG, HUMAN 
CHORIONIC GONADOTROPIN; IU, INTERNATIONAL UNIT; NSGCT, NON-SEMINOMATOUS GERM 
CELL TUMOR; IGCN, INTRATUBULAR GERM CELL NEOPLASIA 
*BRAIN/BONE IMAGING WAS NOT MANDATORY
+
RISK PER IGCCCG CLASSIFICATION 
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Table 2. Comparison of Survival Outcomes between the IGCCCG, IU and NCI SEER 
Dataset 
RISK PER 
IGCCCG 
CRITERIA 
5-YEAR INDIANA UNIVERSITY 
1998-2014 
IGCCCG 
1975-1990 
NCI SEER 
2000-2013 
GOOD RISK PFS 
OS 
90% 
97% 
88% 
91% 
NA 
INTERMEDIATE 
RISK 
PFS 
OS 
84% 
92% 
75% 
79% 
NA 
POOR RISK PFS 
OS 
54% 
73% 
41% 
48% 
NA 
TESTIS CANCER 
COHORT  
OS 94% NA 75% 
Abbreviations: IGCCCG, International Germ Cell Cancer Collaborative 
Group; PFS, progression-free survival; OS, overall survival, NCI SEER: 
National Cancer Institute Surveillance, Epidemiology, and End Results 
Program. 
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Figure. S1 
Abbreviations: *Risk is per International Germ Cell Cancer Collaborative Group criteria; NED, no 
evidence of disease; GCT, germ-cell tumor 
Assess for eligibility 
(N=1611) 
Evaluable Patients 
(N=704) 
Presented to our muti-D 
clinic after receiving initial 
chemotherapy elsewhere 
(N=907) 
Poor Risk*  
N=181 (26%) 
Intermediate Risk* 
N=74 (10%) 
Good Risk*  
N=449 (64%) 
NED (N=434) 
Alive with disease (N=2) 
Dead of GCT (N=5) 
Dead of other etiology (N=8) 
NED (N=68) 
Alive with disease (N=1) 
Dead of GCT (N=3) 
Dead of other etiology (N=2) 
NED (N=133) 
Alive with disease (N=1) 
Dead of GCT (N=44) 
Dead of other etiology (N=3) 
Page 34 of 35Annals of Oncology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Medical Records & 
Pathology slides requested 
Info package mailed 
MDs identified 
Visit scheduled 
Pathology 
review of 
submitted slides 
Clinic visit & 
Imaging review 
Thoracic 
Oncology 
Medical 
Oncology 
Urological 
Oncology 
Treatment plan 
Case Discussion 
Clinical trials 
eligibility 
assessment 
Tumor board for 
complex cases 
Letter to 
referring 
physician 
Page 35 of 35 Annals of Oncology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Page 36 of 35Annals of Oncology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
